Inventor · disambiguated record
Michael P. Arend
Also filed as: AREND MICHAEL · AREND MICHAEL P
37 granted patents·20 pending applications·614 citations·filing 2002–2021
98Inventor score
Top patents by PatentIndex Score
57 records- 0198US7323475B2Nitrogen-containing heteroaryl compounds and methods of use thereofFIBROGEN INC·Filed 2004·Granted Jan 29, 2008·97 cites·46 claims
- 0297US8883823B2Crystalline forms of a prolyl hydroxylase inhibitorFIBROGEN INC·Filed 2013·Granted Nov 11, 2014·20 cites·52 claims
- 0397US7629357B2Nitrogen-containing heteroaryl compounds and methods of user thereofFIBROGEN INC·Filed 2006·Granted Dec 8, 2009·38 cites·52 claims
- 0496US8017625B2Nitrogen-containing heteroaryl compounds and methods of use thereofFIBROGEN INC·Filed 2008·Granted Sep 13, 2011·42 cites·47 claims
- 0596US7863292B2Nitrogen-containing heteroaryl compounds and methods of use thereofFIBROGEN INC·Filed 2007·Granted Jan 4, 2011·28 cites·38 claims
- 0695US8765956B2Nitrogen-containing heteroaryl compounds and methods of use thereofFIBROGEN INC·Filed 2013·Granted Jul 1, 2014·19 cites·19 claims
- 0795US8278325B2Nitrogen-containing heteroaryl compounds and methods of use thereofAREND MICHAEL P·Filed 2011·Granted Oct 2, 2012·22 cites·24 claims
- 0895US7928120B2Cyanoisoquinoline compounds and methods of use thereofFIBROGEN INC·Filed 2007·Granted Apr 19, 2011·40 cites·36 claims
- 0995US7696223B2Pyrrolo- and Thiazolo-pyridine compounds, and methods of use thereofFIBROGEN INC·Filed 2007·Granted Apr 13, 2010·54 cites·32 claims
- 1093US10927081B2Enhanced erythropoiesis and iron metabolismFIBROGEN INC·Filed 2018·Granted Feb 23, 2021·3 cites·46 claims
- 1193US9371288B2Crystalline forms of a prolyl hydroxylase inhibitorFIBROGEN INC·Filed 2014·Granted Jun 21, 2016·7 cites·5 claims
- 1293US8916585B2Nitrogen-containing heteroaryl compounds and methods of use thereofAREND MICHAEL P·Filed 2012·Granted Dec 23, 2014·16 cites·27 claims
- 1393US8759373B2Cyanoisoquinoline compounds and methods of use thereofAREND MICHAEL P·Filed 2012·Granted Jun 24, 2014·21 cites·33 claims
- 1493US8269008B2Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditionsAREND MICHAEL P·Filed 2008·Granted Sep 18, 2012·37 cites·32 claims
- 1592US9695170B2Naphthyridine derivatives as inhibitors of Hypoxia inducible factor (HIF) hydroxylaseFIBROGEN INC·Filed 2016·Granted Jul 4, 2017·5 cites·32 claims
- 1692US9115085B2Crystalline forms of a prolyl hydroxylase inhibitorFIBROGEN INC·Filed 2013·Granted Aug 25, 2015·12 cites·11 claims
- 1792US8466172B2Stabilization of hypoxia inducible factor (HIF) alphaGUENZLER-PUKALL VOLKMAR·Filed 2010·Granted Jun 18, 2013·18 cites·8 claims
- 1891US9340511B2Process for making isoquinoline compoundsFIBROGEN INC·Filed 2013·Granted May 17, 2016·16 cites·48 claims
- 1991US9271970B2Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylaseFIBROGEN INC·Filed 2014·Granted Mar 1, 2016·7 cites·30 claims
- 2091US8921389B2Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylaseNG DANNY·Filed 2012·Granted Dec 30, 2014·17 cites·26 claims
- 2190US9339527B2Nitrogen-containing heteroaryl compounds and methods of use thereofFIBROGEN INC·Filed 2014·Granted May 17, 2016·7 cites·20 claims
- 2290US8952160B2Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activityZHOU XIAOTI·Filed 2009·Granted Feb 10, 2015·18 cites·11 claims
- 2389US11680047B2Enhanced erythropoiesis and iron metabolismFIBROGEN INC·Filed 2020·Granted Jun 20, 2023·1 cites·23 claims
- 2489US9918977B2Crystalline forms of a prolyl hydroxylase inhibitorFIBROGEN INC·Filed 2016·Granted Mar 20, 2018·3 cites·13 claims
- 2588US10272078B2Crystalline forms of a prolyl hydroxylase inhibitorFIBROGEN INC·Filed 2018·Granted Apr 30, 2019·2 cites·6 claims
- 2688US9617218B2Crystalline forms of a prolyl hydroxylase inhibitorFIBROGEN INC·Filed 2015·Granted Apr 11, 2017·5 cites·6 claims
- 2788US9387200B2Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activityFIBROGEN INC·Filed 2015·Granted Jul 12, 2016·5 cites·17 claims
- 2888US9174976B2Cyanoisoquinoline compounds and methods of use thereofFIBROGEN INC·Filed 2014·Granted Nov 3, 2015·9 cites·41 claims
- 2987US10092558B2Nitrogen-containing heteroaryl compounds and methods of use thereofFIBROGEN INC·Filed 2016·Granted Oct 9, 2018·3 cites·20 claims
- 3087US9708269B2Process for making isoquinoline compoundsFIBROGEN INC·Filed 2016·Granted Jul 18, 2017·6 cites·9 claims
- 3187US8703795B2Thienopyridine compounds, and methods of use thereofTURTLE ERIC D·Filed 2006·Granted Apr 22, 2014·17 cites·14 claims
- 3285US9000006B2Thienopyridine compounds, and methods of use thereofFIBROGEN INC·Filed 2014·Granted Apr 7, 2015·7 cites·14 claims
- 3382US10118897B2Crystalline forms of a prolyl hydroxylase inhibitorFIBROGEN INC·Filed 2017·Granted Nov 6, 2018·2 cites·18 claims
- 3480US9643928B2Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acidFIBROGEN INC·Filed 2014·Granted May 9, 2017·4 cites·39 claims
- 3580US9409892B24-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitorsFIBROGEN INC·Filed 2013·Granted Aug 9, 2016·6 cites·30 claims
- 3679US2021369702A1Methods for treating anemia in subjects having kidney failure using inhibitors of hypoxia-inducible factor (hif) hydroxylaseFIBROGEN INC·Filed 2021·Application pending·0 cites
- 3775US11229637B2Nitrogen-containing heteroaryl compounds and methods of use thereofFIBROGEN INC·Filed 2020·Granted Jan 25, 2022·0 cites·12 claims
- 3871US10646482B2Nitrogen-containing heteroaryl compounds and methods of use thereofFIBROGEN INC·Filed 2018·Granted May 12, 2020·0 cites·20 claims
- 3967US2015080425A1Methods for treating anemia in subjects having kidney failure using inhibitors of hypoxia-inducible factor (hif) hydroxylaseKLAUS STEPHEN J·Filed 2014·Application pending·0 cites
- 4066US2020115344A1Crystalline forms of a prolyl hydroxylase inhibitorFIBROGEN INC·Filed 2019·Application pending·0 cites
- 4165US2017312268A1Methods for treating a neurological disorder in a subject using inhibitors of hypoxia-inducible factor (hif) proyl hydroxylaseFIBROGEN INC·Filed 2017·Application pending·0 cites
- 4264US2007155784A1Novel nitrogen-containing heteroaryl compounds and methods of use thereofFIBROGEN INC·Filed 2006·Application pending·0 cites
- 4364US2019276408A1Crystalline forms of a prolyl hydroxylase inhibitorFIBROGEN INC·Filed 2018·Application pending·0 cites
- 4463US2013245037A1Stabilization of Hypoxia Inducible Factor (HIF) AlphaGUENZLER-PUKALL VOLKMAR·Filed 2013·Application pending·0 cites
- 4563US2013203805A1Methods for treating anemia using inhibitors of hypoxia-inducible factor (HIF) hydroxylaseKLAUS STEPHEN J·Filed 2012·Application pending·0 cites
- 4662US2006270699A1Stabilization of hypoxia inducible factor (HIF) alphaFIBROGEN INC·Filed 2006·Application pending·0 cites
- 4762US2006258660A1Stabilization of hypoxia inducible factor (HIF) alphaFIBROGEN INC·Filed 2006·Application pending·0 cites
- 4862US2006258702A1Stabilization of hypoxia inducible factor (HIF) alphaFIBROGEN INC·Filed 2006·Application pending·0 cites
- 4961US2006178317A1Methods of increasing endogenous erythropoietin (EPO)FIBROGEN INC·Filed 2006·Application pending·0 cites
- 5061US2006183695A1Methods of increasing endogenous erythropoietin (EPO)FIBROGEN INC·Filed 2006·Application pending·0 cites
Showing the top 50 of 57 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →